BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24173088)

  • 1. Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy.
    Honda A; Nakamura F; Nannya Y; Shintani Y; Fukayama M; Ichikawa M; Kurokawa M
    Ann Hematol; 2014 Jun; 93(6):1073-4. PubMed ID: 24173088
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diagnostic difficulties caused by a pulmonary infiltrate].
    Simon Z; Jóna A; Miltényi Z; Páyer E; Lieber A; Szilasi M; Illés A
    Orv Hetil; 2012 Jul; 153(27):1077-81. PubMed ID: 22759748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma].
    Torrent A; Navarro JT; Andreo FC; Ribera JM
    Med Clin (Barc); 2013 Aug; 141(3):134-5. PubMed ID: 23332624
    [No Abstract]   [Full Text] [Related]  

  • 4. Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion.
    McGrath SE; Webb A; Walker-Bone K
    J Clin Oncol; 2013 Feb; 31(4):e51-2. PubMed ID: 23270004
    [No Abstract]   [Full Text] [Related]  

  • 5. Pericardial effusion due to pericardium involvement by Hodgkin's lymphoma.
    Guastafierro S; Cappabianca S; Falcone U
    Ann Hematol; 2013 Jun; 92(6):853-4. PubMed ID: 23196418
    [No Abstract]   [Full Text] [Related]  

  • 6. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodular sclerosing Hodgkin disease presenting as a sternal mass.
    Priola SM; Priola AM; Cataldi A; Fava C
    Br J Haematol; 2006 Dec; 135(5):594. PubMed ID: 17107345
    [No Abstract]   [Full Text] [Related]  

  • 9. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.
    Pinto A; Corazzelli G
    Br J Haematol; 2015 Nov; 171(4):665-8. PubMed ID: 25892204
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive pericardial effusion during chemotherapy for advanced Hodgkin lymphoma.
    Casey DJ; Kim AY; Olszewski AJ
    Am J Hematol; 2012 May; 87(5):521-4. PubMed ID: 22120982
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
    Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematuria--a rare presentation of Hodgkin lymphoma.
    Dembla V; Walker BN; Elkins SL; Files JC
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):788-90; discussion 791-2. PubMed ID: 22252582
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
    Evens AM; Cilley J; Ortiz T; Gounder M; Hou N; Rademaker A; Miyata S; Catsaros K; Augustyniak C; Bennett CL; Tallman MS; Variakojis D; Winter JN; Gordon LI
    Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hodgkin lymphoma--ABVD regimen].
    Nagai H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():642-5. PubMed ID: 25831839
    [No Abstract]   [Full Text] [Related]  

  • 16. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classical Hodgkin's lymphoma associated with Langerhans cell histiocytosis: multiagent chemotherapy resulted in histologic resolution of both the classical Hodgkin's lymphoma and Langerhans cell proliferation components.
    Greaves WO; Bueso-Ramos C; Fayad L
    J Clin Oncol; 2011 Feb; 29(4):e76-8. PubMed ID: 21041711
    [No Abstract]   [Full Text] [Related]  

  • 20. Presentation of Hodgkin's lymphoma with Ophelia syndrome.
    Olmos D; Rueda A; Jurado JM; Alba E
    J Clin Oncol; 2007 May; 25(13):1802-3. PubMed ID: 17470872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.